Given the broad availability of SPECT/CT devices, lower instrumentation and radionuclide costs, SPECT/CT systems have huge prospects for application to improve PSMA imaging capacity as more patients with prostate cancer undergo PSMA imaging. This evidence concerns the gene FOLH1 and prostate cancer.